Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study

What Was Tested

Researchers studied NAD+ in this randomized controlled trial publication.

The study evaluated how ingestion of nicotinamide mononucleotide (NMN) for 12 weeks by older adults affected blood nicotinamide adenine dinucleotide (NAD +) levels and physical function, particularly walking function.

Information concerning sleep, and stress was also collected as secondary endpoints.

Who Took Part

The study group was 12 adults.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Neither the adults nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Some adults received a placebo instead of NAD+, giving a reference point.

The NAD+ group and the comparison group ran side by side rather than switching.

A time span of 12 weeks appears in the methods.

What Was Measured

The study evaluated how ingestion of nicotinamide mononucleotide (NMN) for 12 weeks by older adults affected blood nicotinamide adenine dinucleotide (NAD +) levels and physical function, particularly walking function.

Information concerning sleep, and stress was also collected as secondary endpoints.

Topics PubMed links to this paper include Dietary Supplements, NAD, Nicotinamide Mononucleotide, Sleep Quality and Walking Speed.

Author keywords: Blood NAD + and Older adults.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of NAD+ in 12 adults over 12 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (GeroScience), a journal based in Switzerland.

More context: the NAD+ compound page, all human trials.